JAK1 and rheumatoid arthritis: To this end, we focused on filgotinib, a small molecule JAK1 inhibitor initially identified in cellular assays42 and has been approved for treating rheumatoid arthritis patients in Europe and Japan with ongoing clinical trials largely in the US (such as NCT05090410 and reviewed in ref. 43).